Gary Strauss, USA TODAY
2012 is shaping up as another year for the $50 million + CEO.
Friday, three more companies reported their CEOs as the latest members of the $50 million (and up) club; American Express CEO Ken Chenault; Allergan's David Pyott and Gilead Sciences' John Martin.
Lockheed Martin Chairman Robert Stevens fell short of that mark, but still pulled in compensation and stock and options gains valued at $42.5 million, the military contractor says.
At least 15 CEOs of publicly traded companies pulled in at least $50 million in 2011, including Martin, Tyco International's Ed Breen, Starbuck's Howard Schultz and Qualcomm's Paul Jacobs.
Breen lofted into even more exclusive territory last year, when he received a platinum parachute valued at more than $150 million after retiring from the industrial conglomerate in September. He'll soon be joined by Heinz CEO Bill Johnson, who could haul in $212 million this year, once the company is taken private by investors Berkshire Hathaway and 3G Capital later this year.
Biotech giant Gilead said Martin gained $77.1 million exercising previously awarded stock options and added $3.4 million from shares that vested. That's on top of pay, equity and incentive awards valued at $15.3 million. That tops Martin's 2011 compensation and gains from stock and stock options, valued at $54.5 million.
Gilead said shareholder return was up a whopping 80% last year. Martin, 61, has been CEO since 1996.
American Express valued Chenault's compensation at about $28 million, up from $22.5 million in 2011. The financial services firm doubled his annual bonus to $4 million and awarded him stock valued at $18.8 million, up from a $15.3 million stock award in 2011. Chenault gained another $24 million exercising previously awarded stock options and vested shares.
American Express says shareholders received a total return of 24% in 2012, outperforming the Standard & Poor's 500 by eight percentage points.
"Against the backdrop of a slow-growth environment, American Express delivered a strong total shareholder return by controlling expenses, improving credit quality and generating higher revenues in all of our major business segments," the company says in its proxy.
Chenault, 61, was named CEO in 2001.
Pyott received compensation valued at about $19.4 million, up from about $11.9 million in 2011. He gained another $36.6 million from vested shares and exercising previously awarded stock options That's up from 2011, when Pyott gained $30.6 million from stock options.
Pyott, 59, "has delivered exceptional value'' to shareholders since he was named CEO in January 1998, Allergan said in its proxy.
Allergan is perhaps best known for anti-wrinkle medication Botox. Allergan shares climbed nearly 25% in 2012.
Stevens' 2012 gains include $15 million from vested stock and optioned shares, Lockheed Martin says. Stevens, 61, served as CEO from 2004 to 2012 and has been chairman since January.